Processa Pharmaceuticals, Inc. (PCSA) is a Biotechnology company in the Healthcare sector, currently trading at $2.87. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is PCSA = $9 (+213.6% upside).
Valuation: PCSA trades at a trailing Price-to-Earnings (P/E) of -0.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Net income is $14M (loss), growing at +12.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $0 against $6M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.54 (strong liquidity). Debt-to-assets is 0%. Total assets: $8M.
Analyst outlook: 4 / 5 analysts rate PCSA as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 80/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).
